IRON

SEC source: 0001213900-21-011690 · ownership.xml · derivative · entry 1

Redmond Precillia · CIK 0001843163 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,489

Underlying: Common Stock · 25,489 shares

Expires 2031-02-22

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 23, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-011688 · ownership.xml · derivative · entry 1

Lauder Scott · CIK 0001843157 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 272,615

Underlying: Common Stock · 272,615 shares

Expires 2031-02-22

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 23, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-007732 · ownership.xml · derivative · entry 4

Tananbaum James B. · CIK 0001581754 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 2,928,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer.

F3 · derivative.exercise_date: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer.

F3 · derivative.expiration_date: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC and Foresite Capital Opportunity Management V, LLC are general partners, respectively, of Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P., the sole shareholders of FSD Holdings. Dr. Tananbaum, in his capacity as managing member of each of the general partners, may be deemed to have voting and investment discretion over these shares. Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

SEC source: 0001213900-21-007732 · ownership.xml · nonDerivative · entry 2

Tananbaum James B. · CIK 0001581754 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,928,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC and Foresite Capital Opportunity Management V, LLC are general partners, respectively, of Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P., the sole shareholders of FSD Holdings. Dr. Tananbaum, in his capacity as managing member of each of the general partners, may be deemed to have voting and investment discretion over these shares. Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

SEC source: 0001213900-21-007732 · ownership.xml · nonDerivative · entry 1

Tananbaum James B. · CIK 0001581754 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,500,000

F1 · kind: Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021.

F2 · ownership.nature: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC and Foresite Capital Opportunity Management V, LLC are general partners, respectively, of Foresite Capital Fund V, L.P. and Foresite Capital Opportunity Fund V, L.P., the sole shareholders of FSD Holdings. Dr. Tananbaum, in his capacity as managing member of each of the general partners, may be deemed to have voting and investment discretion over these shares. Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

SEC source: 0001213900-21-007713 · ownership.xml · derivative · entry 4

FS Development Holdings, LLC · CIK 0001820810 · 10% owner · Director by Deputization

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner · Director by Deputization

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner · Director by Deputization

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner · Director by Deputization

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,928,750 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer .

F3 · derivative.exercise_date: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer .

F3 · derivative.expiration_date: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer .

F2 · ownership.direct: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

SEC source: 0001213900-21-007713 · ownership.xml · nonDerivative · entry 2

FS Development Holdings, LLC · CIK 0001820810 · 10% owner · Director by Deputization

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner · Director by Deputization

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner · Director by Deputization

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner · Director by Deputization

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,928,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: In connection with the closing of Gemini Therapeutics, Inc.'s (formerly known as FS Development Corp.) business combination, shares of Class B Common Stock of FS Development Corp. converted into common stock of the Issuer .

F2 · ownership.direct: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

SEC source: 0001213900-21-007713 · ownership.xml · nonDerivative · entry 1

FS Development Holdings, LLC · CIK 0001820810 · 10% owner · Director by Deputization

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner · Director by Deputization

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner · Director by Deputization

Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner · Director by Deputization

Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner · Director by Deputization

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,500,000

F1 · kind: Shares of common stock obtained in private placement of public securities ("PIPE") on February 5, 2021.

F2 · ownership.direct: These shares of the Issuer's common stock are held of record by FS Development Holdings, LLC ("FSD Holdings"). Foresite Capital Management V LLC ("FCMVLLC") and Foresite Capital Opportunity Management V, LLC ("FCOMVLLC") are general partners, respectively, of Foresite Capital Fund V, L.P. ("Capital Fund V L.P.") and Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V .L.P."), the sole shareholders of FSD Holdings. Each of FCMVLLC, FCOMVLLC, Capital Fund V L.P and Opportunity Fund V L.P. disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein.

SEC source: 0001213900-21-020632 · ownership.xml · derivative · entry 1

Uknis Marc · CIK 0001843161 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 277,117

Underlying: Common Stock · 277,117 shares

Expires 2031-02-04

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-020624 · ownership.xml · derivative · entry 1

Redmond Precillia · CIK 0001843163 · Chief People Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,450

Underlying: Common Stock · 77,450 shares

Expires 2031-02-04

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-020627 · ownership.xml · derivative · entry 1

Strapps Walter · CIK 0001849041 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,094

Underlying: Common Stock · 79,094 shares

Expires 2031-02-04

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-020638 · ownership.xml · derivative · entry 1

Ong Tuyen · CIK 0001673178 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,855

Underlying: Common Stock · 58,855 shares

Expires 2031-02-04

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a Service Relationship with the Company.

SEC source: 0001213900-21-020635 · ownership.xml · derivative · entry 1

Lubner David Charles · CIK 0001572000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,855

Underlying: Common Stock · 58,855 shares

Expires 2031-02-04

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a Service Relationship with the Company.

SEC source: 0001213900-21-020623 · ownership.xml · derivative · entry 1

Meyenburg Jason Patrick · CIK 0001709008 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,124,832

Underlying: Common Stock · 1,124,832 shares

Expires 2031-02-04

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-21-020621 · ownership.xml · derivative · entry 1

Lauder Scott · CIK 0001843157 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 243,996

Underlying: Common Stock · 243,996 shares

Expires 2031-02-04

F1 · derivative.exercise_date: This option shall vest and become exercisable over a period of four years from the Vesting Start Date, February 5, 2021 with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, provided that as of each such date the Grantee remains in a business relationship with the Company.

SEC source: 0001213900-20-032139 · ownership.xml · nonDerivative · entry 1

FS Development Holdings, LLC · CIK 0001820810 · 10% owner

Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner

Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner

Tananbaum James B. · CIK 0001581754 · Director · President & CEO · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,500

F1 · date: The transaction was inadvertently omitted from reporting due to an administrative oversight.

F2 · kind: The reported shares of Class A common stock were purchased in a private placement by FS Development Holdings, LLC (the "Sponsor") for $10.00 per share, as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-240098).

F3 · ownership.direct: The Sponsor is the record holder of the shares reported herein. Foresite Capital Fund V, L.P. ("Fund V"), its general partner Foresite Capital Management V, LLC ("FCM V"), and Dr. James Tananbaum, the managing member of FCM V, have voting and investment discretion with respect to the common stock held of record by the Sponsor. Each of Fund V, FCM V, their respective members and Dr. Tananbaum disclaim beneficial ownership of these shares except to the extent of any pecuniary interest therein.